| Title: | Identification of plasma biomarker candidates in glioblastoma using an antibody-array-based proteomic approach |
|---|
| Authors: | ID Zupančič, Klemen (Author)
ID Koršič, Marjan (Author)
ID Verbovšek, Urška (Author)
ID Rožman, Primož (Author)
ID Lah Turnšek, Tamara (Author)
ID Blejec, Andrej (Author)
ID Gruden, Kristina (Author)
ID Motaln, Helena (Author)
ID Knežević, Miomir (Author)
ID Veber, Matija (Author)
ID Herman, Ana (Author) |
|---|
| Files: |  URL - Presentation file, visit http://www.degruyter.com/view/j/raon.2014.48.issue-3/raon-2014-0014/raon-2014-0014.xml?format=INT
 PDF - Presentation file, download (621,07 KB)
MD5: D30E197A64963B5C4830441C4E10EECD
URL - Source URL, visit https://doi.org/10.2478/raon-2014-0014
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  NIB - National Institute of Biology
|
|---|
| Abstract: | Background. Glioblastoma multiforme (GBM) is a brain tumour with a very high patient mortality rate, with a median survival of 47 weeks. This might be improved by the identification of novel diagnostic, prognostic and predictive
therapy-response biomarkers, preferentially through the monitoring of the patient blood. The aim of this study was to define the impact of GBM in terms of alterations of the plasma protein levels in these patients.
Materials and methods. We used a commercially available antibody array that includes 656 antibodies to analyse
blood plasma samples from 17 healthy volunteers in comparison with 17 blood plasma samples from patients with
GBM.
Results. We identified 11 plasma proteins that are statistically most strongly associated with the presence of GBM.
These proteins belong to three functional signalling pathways: T-cell signalling and immune responses; cell adhesion and migration; and cell-cycle control and apoptosis. Thus, we can consider this identified set of proteins as potential diagnostic biomarker candidates for GBM. In addition, a set of 16 plasma proteins were significantly associated with the overall survival of these patients with GBM. Guanine nucleotide binding protein alpha (GNAO1) was associated with both GBM presence and survival of patients with GBM.
Conclusions. Antibody array analysis represents a useful tool for the screening of plasma samples for potential cancer biomarker candidates in small-scale exploratory experiments; however, clinical validation of these candidates requires their further evaluation in a larger study on an independent cohort of patients. |
|---|
| Keywords: | glioblastoma, proteomics, biomarker |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Publication date: | 04.12.2014 |
|---|
| Year of publishing: | 2014 |
|---|
| Number of pages: | str. 257-266, III |
|---|
| Numbering: | Vol. 48, no. 3 |
|---|
| PID: | 20.500.12556/DiRROS-5185  |
|---|
| ISSN: | 1318-2099 |
|---|
| UDC: | 616.831-006-07 |
|---|
| DOI: | 10.2478/raon-2014-0014 |
|---|
| COBISS.SI-ID: | 31525081 |
|---|
| Publication date in DiRROS: | 02.08.2024 |
|---|
| Views: | 330 |
|---|
| Downloads: | 246 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
